SEC Form 4 · accession 0001179110-18-003853

ACCELERON PHARMA INC · XLRN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 6, 2018

Accepted (ET)

Mar 8, 2018 · 4:11 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001280600

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 6, 2018	M	37,500	$5.08	A	68,750	D
Common Stock^F1	Mar 6, 2018	S	34,598	$41.34	D	34,152	D
Common Stock^F2	Mar 6, 2018	S	2,902	$42.32	D	31,250	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option to Purchase Common Stock^F3	$5.08	Mar 6, 2018	M	37,500	D	—	Mar 27, 2018	Common Stock	37,500	0	D

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.98 to $41.97 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.98 to $42.70 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3The options of registrants common stock vested as to one third of the shares annually beginning on the first anniversary of the grant.